Arcutis Biotherapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Arcutis Biotherapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.2%
Buyback Yield
| Total Shareholder Yield | -0.2% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case
Feb 26Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Dec 09
Results: Arcutis Biotherapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit
Oct 31
Very Bullish
It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.Revenues Not Telling The Story For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) After Shares Rise 27%
Oct 02Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load?
Jul 15Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
May 09
FDA PDUFA Date And Payer Expansion Will Unlock Opportunity
Expanding ZORYVE's indications and payer coverage is expected to significantly boost revenue and market potential.Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets
Apr 19Arcutis Biotherapeutics: Topical Derm Player Continues To Execute
Mar 12Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up
Mar 09Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations
Feb 26Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period
Jan 23Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jan 02There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump
Nov 27Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Nov 15Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ARQT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARQT's dividend payments have been increasing.
Dividend Yield vs Market
| Arcutis Biotherapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ARQT) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Biotechs) | 2.2% |
| Analyst forecast (ARQT) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate ARQT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARQT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ARQT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ARQT has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 15:20 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arcutis Biotherapeutics, Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard J. Law | Goldman Sachs |
| null null | Guggenheim Securities, LLC |
| Seamus Fernandez | Guggenheim Securities, LLC |